The predictive capacity of in vitro preclinical models to evaluate drugs for the treatment of retinoblastoma.
Exp Eye Res
; 230: 109447, 2023 05.
Article
em En
| MEDLINE
| ID: mdl-36940901
ABSTRACT
Retinoblastoma is a rare childhood cancer of the eye. Of the small number of drugs are used to treat retinoblastoma, all have been repurposed from drugs developed for other conditions. In order to find drugs or drug combinations better suited to the improved treatment of retinoblastoma, reliable predictive models are required, which facilitate the challenging transition from in vitro studies to clinical trials. In this review, the research performed to date on the development of 2D and 3D in vitro models for retinoblastoma is presented. Most of this research was undertaken with a view to better biological understanding of retinoblastoma, and we discuss the potential for these models to be applied to drug screening. Future research directions for streamlined drug discovery are considered and evaluated, and many promising avenues identified.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Retinoblastoma
/
Neoplasias da Retina
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Child
/
Humans
Idioma:
En
Revista:
Exp Eye Res
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Suíça